drugset / Trial / NCT05012319

Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19

NCT05012319

Phase 3 Unknown 500 enrolled Salmaniya Medical Complex
RandomizedParallel-groupTriple-blindTreatment

Summary

Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection. thru facility).

Timeline

Start
2021-08-05
Primary completion
2022-03-30
Completion
2022-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified Intranasal

Indications